A5071384531- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Peptidase Inhibition and Analysis
- Retinoids in leukemia and cellular processes
- MicroRNA in disease regulation
- Cancer Treatment and Pharmacology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- RNA modifications and cancer
- CNS Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Histone Deacetylase Inhibitors Research
- Chronic Myeloid Leukemia Treatments
- Cancer-related gene regulation
- Cancer-related molecular mechanisms research
- Hematological disorders and diagnostics
- Acute Lymphoblastic Leukemia research
- Hepatitis B Virus Studies
- Immune Cell Function and Interaction
- Eosinophilic Disorders and Syndromes
- Bone and Joint Diseases
University of Hong Kong
2015-2025
Hong Kong Sanatorium and Hospital
2022-2025
Queen Mary Hospital
2014-2023
University of Dundee
2018
NYU Langone Health
2018
National and Kapodistrian University of Athens
2015
University Hospital Heidelberg
2015
Heidelberg University
2015
Carolinas Healthcare System
2015
Chinese University of Hong Kong
1999-2014
The aim of International Myeloma Working Group was to develop practical recommendations for the use magnetic resonance imaging (MRI) in multiple myeloma (MM).An interdisciplinary panel clinical experts on MM and bone disease developed value MRI based data published through March 2014.MRI has high sensitivity early detection marrow infiltration by cells compared with other radiographic methods. Thus, detects involvement patients much earlier than myeloma-related destruction, no radiation...
miR-124-1 is a tumour suppressor microRNA (miR). Epigenetic deregulation of miRs implicated in carcinogenesis. Promoter DNA methylation and histone modification was studied 5 normal marrow controls, 4 lymphoma, 8 multiple myeloma (MM) cell lines, 230 diagnostic primary samples acute myeloid leukaemia (AML), lymphoblastic (ALL), chronic (CML), lymphocytic (CLL), MM, non-Hodgkin's lymphoma (NHL), 53 MM at stable disease or relapse. unmethylated controls but homozygously methylated lines....
The surface molecule CD56 marks a category of malignant lymphoma putative natural killer (NK) cell origin. We conducted retrospective analysis 24 cases CD56+ NK lymphoma/leukaemia to define the clinicopathologic and prognostic features this specific group lymphomas. 56 nasal lymphomas 204 with an initial diagnosis peripheral T-cell were retrospectively analysed. To specifically examine origin, only those that negative for expression CD3 but positive identified. predominant sites involvement...
miR-34a is a transcriptional target of p53 and implicated in carcinogenesis. We studied the role methylation panel hematological malignancies including acute leukemia [acute myeloid (AML) lymphoblastic (ALL)], chronic [chronic lymphocytic (CLL) (CML)], multiple myeloma (MM) non-Hodgkin's lymphoma (NHL). The status promoter was 12 cell lines 188 diagnostic samples by methylation-specific polymerase chain reaction. unmethylated normal controls but methylated 75% 37% lines. Hypomethylating...
The incidence of multiple myeloma (MM) is known to be variable according ethnicity. However, the differences in clinical characteristics between ethnic groups are not well‐defined. In Asian countries, although MM has been lower than that Western there growing evidence increasing rapidly. Myeloma Network decided initiate first multinational project describe and practices Asia. Data were retrospectively collected from 23 centers 7 countries regions. at diagnosis, survival rates initial...
The multicenter retrospective study conducted in 38 centers from 20 countries including 172 adult patients with CNS MM aimed to describe the clinical and pathological characteristics outcomes of multiple myeloma (MM) involving central nervous system (CNS). Univariate multivariate analyses were performed identify prognostic factors for survival. median time diagnosis was 3 years. Thirty‐eight (22%) diagnosed involvement at initial 134 (78%) relapse/progression. Upon MM, 97% received therapy...
Primary solitary extramedullary and multiple plasmacytomas are rare manifestations of plasma cell tumors. This study reviews their imaging spectrum in 12 patients.Imaging features primary nonspecific but compatible with solid tumors that isointense on T1-weighted images iso- to hyperintense T2-weighted relative muscle white matter variable enhancement. Large may show necrosis destruction, infiltration, or encasement adjacent structures. Multiplicity lesions regional lymphadenopathy were...
miR-203 is a tumour suppressor microRNA (miRNA). We studied the methylation of hsa-miR-203 in 150 samples including acute myeloid leukaemia (AML), lymphoblastic (ALL), chronic (CML), lymphocytic (CLL) and non-Hodgkin's lymphoma (NHL) by methylation-specific PCR, miRNA expression stem-loop RT-qPCR. promoter was unmethylated normal controls but homozygously methylated two AML four cell lines, which 5-Aza-2'-deoxycytidine treatment led to demethylation re-expression. Restoration cells inhibited...
PURPOSE: To investigate the frequency of p15 and p16 gene promoter methylation in acute promyelocytic leukemia (APL), to define its value detection minimal residual disease (MRD) treatment prognostication. PATIENTS AND METHODS: Bone marrow DNA obtained from 26 patients with APL at diagnosis during follow-up was studied methylation-specific polymerase chain reaction (MS-PCR). Serial by MS-PCR for MRD, disease-free overall survival were correlated status diagnosis. RESULTS: has a maximum...